Lupin Wins FDA Nod for Risperidone

  Published 9 months ago

Lupin gained USFDA approval for Risperidone LAI, leveraging Nanomi technology, securing 180-day CGT exclusivity.

  • Risperidone LAI treats schizophrenia, bipolar I disorder and is bioequivalent to Risperdal Consta long-acting injection.
  • Lupin’s first Nanomi-based product approval validates its LAI platform, strengthening its specialty injectables pipeline and innovation strategy.
  • IQVIA reported annual US sales for Risperidone extended-release injectable suspension estimated at $190 million.

You might like these

MoD Capital Spend Over Half FY 2025‑26

JK Paper Sees Profit Dip, Eyes Growth

Hindalco to Acquire EMIL Mines and Mineral Resources

Trump's Tariffs & Harvard Clash: US Soft Power at Risk

Snowman Logistics Q1 Profit Surges 57%

ITC Q2 FY26: Steady Growth Amid Challenges

AI-Driven Public Health Push in India

News that matters the most ⚡